Human study to evaluate the effect and safety of oraCMS1 ? (Weissella cibaria CMS1) intake on upper respiratory infections and oral inflammation

Seoul Metropolitan Government Seoul National University Boramae Medical Center0 个研究点目标入组 90 人开始时间: 待定最近更新: 2023年3月6日

试验速览

暂无简介。

•1) Subject who agreed to participate in this study and signed a written informed consent
•2) Subject aged from 20 to under 70
•3) Subject who have had upper respiratory infections or flu symptoms at least 4 times a year

•1) Subject with symptoms of upper respiratory infection, flu, or suspected COVID-19 infection at the
•first visit
•2) Subject with current clinically significant cardiovascular, immune system, infectious, neoplastic,
•respiratory system diseases
•3) Subject with a history of peritonsillar abscess, rheumatic fever, or glomerulonephritis
•4) Subject with severe gastrointestinal symptoms, gastrointestinal diseases, or have undergone
•gastrointestinal surgery
•5) Subject who are being treated for uncontrolled hypertension, diabetes, thyroid disease, etc.
•6) Subject with mental illness such as depression, schizophrenia, alcoholism, drug addiction, etc.
•7) Subject with serum creatinine is more than twice the normal upper limit of the research institute or
•those whose ALT and AST levels are more than three times the normal upper limit of the research
•8) Subject who received antibiotics or drugs that may affect immune function within 1 month of the
•first visit
•9) Subject who have consistently consumed probiotics products or health functional foods that may
•affect immunity within one month of the first visit.

发起方

Seoul Metropolitan Government Seoul National University Boramae Medical Center